Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease
Julie Morisset(Centre Hospitalier de l’Université de Montréal), Joyce Lee(Inserm), Xiaowen Hu(Lanzhou University), Paul J. Wolters(University of California, San Francisco), Kirk D. Jones, Brett Ley(University of California, San Francisco), Talmadge E. King(University of California, San Francisco), Jay H. Ryu(Mayo Clinic), Harold R. Collard(University of California, San Francisco), Brett M. Elicker, Stephanie T. Le(University of California, San Francisco)
Cited by 1
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
|The Lancet|2011|2.1k
Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis
|Nature Communications|2020|780